Recent Updates
Recently added Catalysts
ELAN Negative Sentiment Score: 20/100

ELANCO ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Elanco Animal Health Incorporated and Encourages Investors to Contact the Firm

Key Takeaway: Elanco Animal Health Incorporated is facing a class action lawsuit filed by Bragar Eagel & Squire, P.C. in the U.S. District Court for Maryland. The lawsuit alleges that the company provided materially false and misleading statements regarding its products, particularly Zenrelia, and its business prospects during the class period from November 7, 2023, to June 26, 2024. Key accusations include misleading safety information about Zenrelia and the likelihood of meeting regulatory approval timelines for its products. Investors impacted by these claims have until December 6, 2024, to apply as lead plaintiffs in the suit.

Market Sentiment Analysis

CONCERNS & RISKS

  • Class action lawsuit filed due to misleading statements about business prospects.
  • Allegations include that Zenrelia was less safe than communicated to investors.
  • Company is unlikely to meet the timelines for regulatory approval of Zenrelia and Credelio Quattro.
  • Public statements made by the company were deemed materially false and misleading.

Full Press Release Details

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSE: ELAN) in the United States District Court for the District of Maryland on behalf of all persons and entities who purchased or otherwise acquired Elanco securities between November 7, 2023 and June 26, 2024, both dates inclusive (the “Class Period”). Investors have until December 6, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) Zenrelia was less safe than the Company had led investors to believe; (2) Elanco was unlikely to meet its own previously issued timeline for the U.S. approval and commercial launch of both Zenrelia and Credelio Quattro; (3) accordingly, the Company's business and/or financial prospects were overstated; and (4) as a result, the Company's public statements were materially false and misleading at all relevant times.
If you purchased or otherwise acquired Elanco shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Frequently Asked Questions

What lawsuit was filed against Elanco Animal Health?

A class action lawsuit was filed against Elanco for making misleading statements about its business.

What is the Class Period for this lawsuit?

The Class Period is from November 7, 2023, to June 26, 2024.

Who can apply to be the lead plaintiff?

Investors who purchased Elanco securities during the Class Period can apply by December 6, 2024.

What are the main allegations in the complaint?

The complaint alleges that Elanco misled investors about product safety and timeline for approvals.

How can I contact Bragar Eagel & Squire for more info?

You can email investigations@bespc.com or call 212-355-4648 for more information.

Last updated: Nov 13, 2024